Antibody Therapeutics 
Event Information
Document Title
Event Overview
 |
| |
| ||
Antibody Therapeutics provides a focused look at the preclinical and clinical development of antibody-based drug products. At this year's meeting, you will hear updates of preclinical and clinical stage programs, review the current state of the antibody therapeutics market and learn about trends in IP law that could impact your development candidates.
Antibody Therapeutics Keynote Presentations
| Monoclonal Antibodies in Cancer Therapy: 30 Years of Progress | Therapeutic Antibody Sector Remains Upbeat in Wake of Market Turmoil! | Monoclonal Antibody First-In-Man Studies: A Regulatory Perspective and Recommendations |
Dedicated Antibody Therapeutics Sessions Include:
- Session I: Preclinical Development of Antibody Therapeutics
- Session II: Clinical Development of Cancer Therapeutics (1)
- Session III: Clinical Development of Cancer Therapeutics (2)
- Session IV: Clinical Development of Non-Cancer Therapeutics (1)
- Session V: Clinical Development of Non-Cancer Therapeutics (2)
Your Registration Also Gives You Access and Materials to:
IBC's 19th Annual International Conference
Antibody Engineering
December 7-11, 2008
Antibody Engineering and Immunotherapeutics for the 21st Century
Complete Antibody Engineering Details can be found at:www.IBCLifeSciences.com/antibodyeng
As a registered attendee for the Antibody Therapeutics conference, you will also have access to the sessions and materials of the 19th International Antibody Engineering conference. You may move freely among the sessions of both events and customize your conference experience to meet the needs of you and your organization.
Bottom menu
Copyright IBC Life Sciences, a part of Informa Life Sciences Group